文献速递神经肿瘤

优化胶质母细胞瘤最大范围切除:拉曼光谱与5-氨基乙酰丙酸对比

Optimizing maximum resection of glioblastoma: Raman spectroscopy versus 5-aminolevulinic acid.
PubMed 文献 · J Neurosurg · 2022-12-23

该前瞻性临床试验纳入15例新诊断并经组织学证实的胶质母细胞瘤患者,术中比较5-氨基乙酰丙酸(5-ALA)与拉曼光谱(RS)检测肿瘤浸润脑组织的性能。结果显示,肿瘤核心区两者敏感性均为100%;瘤周组织RS敏感性高于5-ALA(69% vs 46%)但特异性较低(57% vs 81%),联合应用使检测准确率提高约10%。病理导向切除使切除体积较术前对比增强体积增加52%(p=0.0123)。

要点

  • 肿瘤核心区5-ALA与RS敏感性均为100%。
  • 瘤周组织RS敏感性69%高于5-ALA的46%,特异性57%低于5-ALA的81%。
  • 两法联合使肿瘤检测准确率提高约10%。

核心结论

  • 根据研究数据,RS检测肿瘤浸润脑组织的敏感性高于当前标准5-ALA,但特异性较低。
  • 随着技术和流程的进一步改进,RS联合原卟啉IX荧光未来可能有助于病理导向的胶质瘤切除。

研究设计与样本

  • 2020年7月至2021年10月开展的前瞻性临床试验,纳入15例新诊断且组织学证实的胶质母细胞瘤患者。
  • 术中使用5-ALA和RS检测对比增强肿瘤核心与瘤周组织中的癌细胞,以实现病理导向的最大范围切除。
  • 每例从导航引导区域至少取10个活检样本,由两名神经病理学家检查肿瘤细胞存在情况。

主要发现

  • 共获取185个活检样本,来自对比增强肿瘤核心(n=19)和瘤周组织(n=166)。
  • 肿瘤核心区5-ALA和RS敏感性均为100%。
  • 瘤周组织中5-ALA敏感性低于RS(46% vs 69%),但特异性高于RS(81% vs 57%)。
  • 两法联合使肿瘤检测准确率提高约10%。
  • 病理导向切除使切除体积较术前对比增强体积增加52%(p=0.0123)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to assess and compare the potential of 5-aminolevulinic acid (5-ALA) and Raman spectroscopy (RS) in detecting tumor-infiltrated brain in patients with glioblastoma (GBM). METHODS: Between July 2020 and October 2021, the authors conducted a prospective clinical trial with 15 patients who underwent neurosurgical treatment of newly diagnosed and histologically verified GBM. A solid contrast-enhancing tumor core and peritumoral tissue were investigated intraoperatively for cancer cells by using 5-ALA and RS to achieve pathology-tailored maximum resection. In each case, a minimum of 10 biopsies were sampled from navigation-guided areas. Two neuropathologists examined the biopsies for the presence of neoplastic cells. The detection performance of 5-ALA and RS alone and in combination was assessed. Pre- and postoperative MRI, Karnofsky Performance Status (KPS), and National Institutes of Health Stroke Scale (NIHSS) scores were compared, and median progression-free survival (PFS) was evaluated. RESULTS: A total of 185 biopsy samples were harvested from the contrast-enhancing tumor core (n = 19) and peritumoral tissue (n = 166). In the tumor core, 5-ALA and RS each showed a sensitivity of 100%. In the peritumoral tissue, 5-ALA was less sensitive than RS in detecting cancer (46% vs 69%) but showed higher specificity (81% vs 57%). When the two methods were combined, the accuracy of tumor detection was increased by about 10%. Pathology-tailored resection led to a 52% increase in resection volume comparing the volume of preoperative contrast enhancement with the postoperative resection cavity on MRI (p = 0.0123). Eloquent brain involvement prevented gross-total resection in 4 patients. Four weeks after surgery, mean KPS (p = 0.7637) and NIHSS scores (p = 0.3146) were not significantly different from preoperative values. Of the 13 patients who had received postoperative chemoradiotherapy, 4 did not show any progression after a median follow-up of 14 months. The remaining 9 patients had a median PFS of 8 months. CONCLUSIONS: According to the study data, RS is capable of detecting tumor-infiltrated brain with higher sensitivity but lower specificity than the current standard of 5-ALA. With further technological and workflow advancements, RS in combination with protoporphyrin IX fluorescence may contribute to pathology-tailored glioma resection in the future.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Herta J, Cho A, Roetzer-Pejrimovsky T, et al. Optimizing maximum resection of glioblastoma: Raman spectroscopy versus 5-aminolevulinic acid. J Neurosurg. 2022. PMID: 36681953. doi:10.3171/2022.11.JNS22693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。